AI assistant
Lipocine Inc. — Director's Dealing 2018
Jan 3, 2018
35074_dirs_2018-01-02_ebe0532a-1514-4e92-995a-d191a3dfdafa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lipocine Inc. (LPCN)
CIK: 0001535955
Period of Report: 2017-12-29
Reporting Person: Ono Richard Dana (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-29 | Common Stock | M | 1750 | — | Acquired | 5750 | Direct |
| 2017-12-29 | Common stock | S | 875 | $3.4667 | Disposed | 4875 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-29 | Restricted Stock Unit | $0 | M | 1750 | Disposed | 2027-01-25 | Common stock (1750) | Direct |
Footnotes
F1: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4).
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54.
F4: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.